Retrospective study of nivolumab for patients with recurrent high grade gliomas
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-018-2907-4
Abstract: IntroductionPatients with recurrent high-grade gliomas (HGG) have limited treatment options. HGG utilize the PD-1 pathway to evade immune responses. Checkpoint inhibitors have demonstrated safety and clinical activity in patients with recurrent glioblastoma. We explored the… read more here.
Keywords: high grade; received nivolumab; grade gliomas; patients recurrent ... See more keywords
Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.682
Abstract: 682Background: Little data exists on objective response rates (ORR), progression-free survival (PFS), and safety of 2L VEGFR-TKI after 1L ICI therapy in pts with mCCRCC. Methods: This is a retrospective study of pts with mCCRCC… read more here.
Keywords: outcomes patients; line; vegfr tki; received nivolumab ... See more keywords